A
Ability Pharmaceuticals — Series A (estimated) · €7M
Clinical-stage biopharma AbilityPharma raised €7M from a European-Canadian syndicate to fully fund the international Phase 2b trial of its oral autophagy-inducing cancer drug ABTL0812 in metastatic pancreatic cancer, across 23 hospitals in Spain, the US, France and Israel. No series letter was disclosed for the round; the company had also received about €2M in non-dilutive public grants in 2023.
LeadCTI Life Sciences Fund
RoundSeries A (estimated)
Announced11 Mar 2024 · as AbilityPharma
CityCerdanyola del Vallès · reported Barcelona
SectorHealthtech & Bio · Biotech
Source
E
C
E
C
